Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0018133 (
graft-versus-host disease
)
18,032
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
B and T lymphocyte attenuator
(
BTLA
) is a co-inhibitory receptor that interacts with herpesvirus entry mediator (HVEM), and this interaction regulates pathogenesis in various immunologic diseases. In
graft-versus-host disease
(
GVHD
),
BTLA
unexpectedly mediates positive effects on donor T-cell survival, whereas immunologic mechanisms of this function have yet to be explored. In this study, we elucidated a role of
BTLA
in
GVHD
by applying the newly established agonistic anti-
BTLA
monoclonal antibody that stimulates
BTLA
signal without antagonizing
BTLA
-HVEM interaction. Our results revealed that provision of
BTLA
signal inhibited donor antihost T-cell responses and ameliorated
GVHD
with a successful engraftment of donor hematopoietic cells. These effects were dependent on
BTLA
signal into donor T cells but neither donor non-T cells nor recipient cells. On the other hand, expression of
BTLA
mutant lacking an intracellular signaling domain restored impaired survival of
BTLA
-deficient T cells, suggesting that
BTLA
also serves as a ligand that delivers HVEM prosurvival signal in donor T cells. Collectively, current study elucidated dichotomous functions of
BTLA
in
GVHD
to serve as a costimulatory ligand of HVEM and to transmit inhibitory signal as a receptor.
...
PMID:Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway. 2122 Jul 49
Attenuation of T cell-mediated damage of blood endothelial cells (BECs) in transplanted organs is important to prevent transplant vasculopathy (TV) and chronic rejection. Here, we assessed the importance of minor histocompatibility antigen (mHA) distribution and different coinhibitory molecules for T cell-BEC interaction. A transgenic mHA was directed specifically to BECs using the Tie2 promoter and cellular interactions were assessed in
graft-versus-host disease
-like and heterotopic heart transplantation settings. We found that cognate CD4(+) T-cell help was critical for the activation of BEC-specific CD8(+) T cells. However, systemic mHA expression on BECs efficiently attenuated adoptively transferred, BEC-specific CD4(+) and CD8(+) T cells and hence prevented tissue damage, whereas restriction of mHA expression to heart BECs precipitated the development of TV. Importantly, the lack of the coinhibitory molecules programmed death-1 (PD-1) and
B and T lymphocyte attenuator
fostered the initial activation of BEC-specific CD4(+) T cells, but did not affect development of TV. In contrast, TV was significantly augmented in the absence of PD-1 on BEC-specific CD8(+) T cells. Taken together, these results indicate that antigen distribution in the vascular bed determines the impact of coinhibition and, as a consequence, critically impinges on T cell-mediated vascular immunopathology.
...
PMID:Systemic minor histocompatibility antigen expression in blood endothelial cells prevents T cell-mediated vascular immunopathology. 2396 95